Ratings santec Holdings Corporation

Equities

6777

JP3335410001

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-12 am EDT			5-day change	1st Jan Change
8,790 ^JPY	-0.11%		-3.72%	+184.01%

Jan. 24	PRISM BioLab Co.,Ltd announced that it has received ¥1.5 billion in funding from santec Holdings Corporation, Eli Lilly and Company	CI
2023	Santec Holdings Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With a 2025 P/E ratio at 23.5 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Electronic Equipment & Parts

	1st Jan change	Capi.	ESG Refinitiv
SANTEC HOLDINGS CORPORATION	+184.01%	653M	-
KEYENCE CORPORATION	+19.51%	117B	C
HEXAGON AB	+0.70%	30.59B	B-
BOE TECHNOLOGY GROUP COMPANY LIMITED	+10.26%	21.88B	B+
TELEDYNE TECHNOLOGIES INCORPORATED	-11.69%	18.68B	C
KYOCERA CORPORATION	-5.15%	17.64B	C+
ZEBRA TECHNOLOGIES CORPORATION	+18.97%	16.88B	C+
HALMA PLC	+16.94%	12.99B	B
FLEX LTD.	-0.21%	12.01B	A
MINEBEAMITSUMI INC.	+22.96%	9.15B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes